*United States Patent 12,606,869 (Iloperidone/CYP2D641 Genotype-Titrated Dosing to Reduce QTc Risk): Scope, Claim-by-Claim Analysis, and US Patent Landscape**
Executive summary: US Patent 12,606,869 claims genotype-guided iloperidone (or metabolite) dose reduction in patients with *CYP2D6 reduced metabolism determined by presence of two CYP2D641 alleles, linking that genotype to lower QTc prolongation risk via administration of 25%, 50%, or 75% of an assumed 24 mg/day wild-type exposure dose (with explicit numeric exemplars including ~6 mg/day, 12 mg/day, and 18 mg/day) and controlled dosing regimens (including bid). The enforceable core is the combination of (i) CYP2D641/41 genotyping, (ii) a specified fraction of 24 mg/day, and (iii) a QTc-risk reduction** limitation. Design-around risk is driven by how strictly a challenger must avoid those three elements together.
*What patents protect iloperidone dosing based on CYP2D641 genotype to reduce QTc prolongation in the US?**
US 12,606,869 protects methods of treatment where iloperidone (or a metabolite) is dosed according to a CYP2D641/41 genotype status and where the claimed regimen is tied to lower QTc prolongation risk than the “wild-type” reference dose.
Patent claims at a glance (high-level scope map)
| Claim set |
Key protected elements |
Patient population |
Dose concept |
QTc limitation |
Genotyping limitation |
| Claim 1 |
Schizophrenia; iloperidone or metabolite; CYP2D6 reduced metabolism; genotype includes *two CYP2D641 alleles; administer 25/50/75% of 24 mg/day; lower QTc risk** vs 24 mg/day |
Schizophrenia |
25%, 50%, 75% of 24 mg/day |
Expressly lower QTc risk |
Genotype determination via genotyping assay |
| Claim 2 |
Adds sequencing/probe-based assay specifics |
Schizophrenia |
Same as claim 1 |
Same as claim 1 |
DNA/mRNA extraction, PCR/amplification, sequencing/hybridization to probes to detect CYP2D6*41 allele count |
| Claims 3, 11, 12 |
Adds numeric dose exemplars: about 12 mg/day and 6/18 mg/day |
Schizophrenia |
Fraction-to-absolute examples |
Same as claim 1 |
Same as claim 1 |
| Claim 4 |
Broadens indications (schizoaffective, depression, Tourette’s, psychotic, delusional) |
Schizoaffective/depression/Tourette’s/psychotic/delusional |
25/50/75% of 24 mg/day |
Lower QTc risk vs reference |
CYP2D641/41 determination |
| Claims 5, 6 |
Adds QTc-prolongation risk patient, and numeric dose |
Same as claim 4 |
~12 mg/day |
Same |
Same |
| Claims 7, 8 |
Introduces “at risk for iloperidone-induced QTc prolongation” framing and dose exposure requirement |
Genotype associated with reduced metabolism (CYP2D641/41); also QTc risk |
First amount is 25/50/75% of 24 mg/day; reference dose produces therapeutically effective exposure in wild-type |
Lower QTc risk by design; risk indicated by poor metabolizer genotype presence |
Assay to determine whether patient has poor metabolizer genotype with two *41 alleles |
| Claims 9, 10, 13–18 |
Adds numeric dose examples and metabolite P88 |
Same as claim 1 / claim 4 / claim 7 depending on dependency chain |
~6 mg/day and ~18 mg/day (plus 12 mg/day where applicable) |
Same |
Same |
| Claims 19–20 |
Adds dosing regimen: first amount administered bid |
Same as relevant independent claim |
Same fraction/absolute dose |
Same |
Same |
Core claim interpretation: what you must do to infringe
To fall within claim 1 (the broadest schizophrenia independent claim), an accused method must include all of the following in combination:
- Iloperidone or a metabolite thereof is administered.
- The patient has schizophrenia.
- The clinician determines reduced CYP2D6-mediated metabolism relative to wild type by a genotyping assay that identifies a genotype associated with reduced metabolism that includes *two CYP2D641 alleles* (CYP2D641/*41).
- The clinician administers a dose equal to 25%, 50%, or 75% of 24 mg/day.
- The dose choice is for the purpose/characterization such that QTc prolongation risk is lower for that patient compared to administration of the second amount (the implied 24 mg/day wild-type consistent regimen).
This “combination-and-relationship” structure is important for both enforcement and design-around.
How do claims 1–20 differ, and which limitations are most material for infringement risk?
Claim 1 (Schizophrenia)
Most material limitations
- Indication: schizophrenia
- Genotype: *two CYP2D641 alleles**
- Dosage scale: 25/50/75% of 24 mg/day
- QTc: lower QTc prolongation risk with first amount vs second amount
- Method architecture: sample collection → genotyping assay → genotype determination → administration
Practical enforcement reading: The claim is not merely “dose reduce for CYP2D6.” It requires the *specific genotype presence (two 41 alleles) and the fractional dose relative to 24 mg/day, plus the QTc-risk relationship**.
Claim 2 (Assay specifics)
Adds technical steps:
- Extract genomic DNA or mRNA
- Sequence CYP2D6 DNA derived from extracted material
- Amplify CYP2D6 region to enrich gene-region DNA
- Sequence by hybridizing to nucleic acid probes to determine if patient has genotype including *two CYP2D641 alleles**
Materiality: Claim 2 is narrower than claim 1. It matters most if an accused workflow uses a substantially different genotyping modality or does not include probe/hybridization sequencing as defined.
Claims 3 and 11–13 (Dose exemplars)
- Claim 3: about 12 mg/day
- Claims 11/17: about 6 mg/day
- Claims 12/15/18: about 18 mg/day
Materiality: These define narrower numeric embodiments that could be easier to show if a competitor maps to those absolute targets.
Claim 4 (Indication expansion beyond schizophrenia)
Replaces “suffering from schizophrenia” with:
- schizoaffective disorder, depression, Tourette’s syndrome, psychotic disorder, or delusional disorder
Materiality: Increases potential enforcement surface across psychiatric indications. The genotype and dosing/QTc framework remains.
Claims 5 and 6 (QTc-risk patient qualifier + numeric)
- Claim 5: patient is “at risk for a prolonged QT interval”
- Claim 6: first amount about 12 mg/day
Materiality: Tightens the patient qualifier. If an accused label is broader but the method includes risk stratification, claim 5 can capture.
Claims 7–8 (QTc-induction risk framing and exposure linkage)
- Requires determining patient is at risk for iloperidone-induced QTc prolongation
- Genotype confirmation: “poor metabolizer genotype” including *two CYP2D641 alleles**
- Administer fraction of 24 mg/day such that the second amount causes therapeutically effective blood exposure in wild-type patients
Materiality: The added exposure concept is a meaningful narrowing lens. It can be used to argue that a competitor’s reference dosing does not align with the wild-type exposure benchmark used in the patent.
Claims 10, 13, 16 (Metabolite P88)
Defines metabolite:
- (1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl] propoxy]-3-methoxyphenyl] ethanol) (P88)
Materiality: Extends coverage beyond iloperidone itself to at least the explicitly named metabolite. If a competitor markets a metabolite or uses a prodrug-to-metabolite strategy, this becomes relevant.
Claims 19–20 (Bid dosing requirement)
Adds dosing regimen:
- first amount administered twice daily (bid) divided doses
Materiality: Narrower than base method claims. However, many real-world psychiatric regimens are bid, so this can be practically significant if a competitor’s method mirrors that cadence.
What is the practical claim scope for dose fractions (25%, 50%, 75% of 24 mg/day) and how do the numeric embodiments align?
The patent uses an explicit reference of 24 mg/day as the “wild-type consistent” second amount and then defines first amounts as:
- 25% of 24 mg/day = 6 mg/day
- 50% of 24 mg/day = 12 mg/day
- 75% of 24 mg/day = 18 mg/day
Claims explicitly recite these absolute figures (“about 6,” “about 12,” “about 18”), which reduces room for ambiguity in infringement mapping.
Design-around implications (method claim structure)
- A challenger cannot avoid infringement by using a genotype-confirmed CYP2D641/41 assessment if it still administers one of the claimed fractions and ties it to QTc risk reduction versus the 24 mg/day reference method.
- A challenger may reduce risk by:
- using a different fraction not covered (not 25/50/75), or
- using a different genotype threshold (not “two *41 alleles”), or
- avoiding an express or inherent QTc-risk differential relative to the 24 mg/day second amount.
The claim’s strongest enforceability feature is that it defines both a genotype boundary and a dosing boundary, then requires a QTc-risk relationship.
*How many claim elements relate to CYP2D641 genotyping and assay mechanics?**
Across independent claim 1 and its dependent assay claim 2, the patent’s technical requirements can be grouped into three layers:
-
Genotype requirement
- genotype includes *two CYP2D641 alleles**
-
Assay requirement (functional)
- obtain biological sample
- perform genotyping assay
- determine genotype
-
Assay requirement (mechanistic) in claim 2
- extraction of DNA or mRNA
- sequencing CYP2D6 DNA derived from extraction
- amplification of CYP2D6 region for enrichment
- sequencing by hybridizing to nucleic acid probes
If a competitor uses a different assay modality (e.g., targeted SNP genotyping or non-probe sequencing), claim 2 may be avoided, but claim 1 or 4 or 7 still capture as long as the functional genotype determination for “two *41 alleles” is met.
What indications does US 12,606,869 cover and how broad is its patient population?
Indications by claim
- Schizophrenia: claim 1 and downstream schizophrenia-dependent claims
- Schizoaffective disorder, depression, Tourette’s syndrome, psychotic disorder, delusional disorder: claim 4 and claim 7-linked dependencies
Patient risk qualifiers
- Patient has a genotype associated with reduced CYP2D6-mediated metabolism (CYP2D641/41)
- Additional qualifiers in certain claims:
- risk for prolonged QT interval (claim 5)
- risk for iloperidone-induced QTc prolongation (claim 7)
Net effect: the patent is primarily a pharmacogenetic safety management method with psychiatric indication coverage.
What formulation or API scope is covered: iloperidone vs metabolite P88?
The claims cover:
- “a compound that is iloperidone or a metabolite thereof” (claims 1, 4, 7)
- metabolite P88 is specifically enumerated in claims 10, 13, 16 (and associated with “the metabolite being … (P88)”)
There are no dosage-form limitations in the provided claim set excerpt (e.g., tablet vs liquid). The binding limitation is method dosing, genotype selection, and QTc-risk reduction.
How does the patent landscape for iloperidone safety and CYP2D6 pharmacogenomics typically cluster around claims like these?
Even without citing other specific US numbers here, the claim architecture in 12,606,869 is consistent with a landscape pattern:
- Genotype-linked dosing patents (CYP2D6 poor metabolizers, specific alleles, and dose reduction fractions)
- QTc safety management patents (strategies to reduce QT prolongation through dose and risk identification)
- Assay method patents (DNA/RNA extraction, amplification, sequencing, probe hybridization)
- Exposure-based regimen patents (blood exposure tied to dose selection and therapeutic effectiveness)
This patent is firmly in the overlap of:
- pharmacogenomics (CYP2D641/41)
- cardiac safety (QTc risk)
- dose fraction mapping to a reference 24 mg/day wild-type regimen
What generic entry risks exist for iloperidone methods like this in the US?
Because these are method-of-treatment claims, a generic iloperidone manufacturer that labels product dosing but does not instruct or practice the patented genotype-guided reduction may try to argue non-infringement or that the method is not “used” by the infringer. Enforcement often turns on:
- whether the generic’s product is actually used in a way that meets the claimed steps,
- whether FDA labeling or clinical practice guidance includes the patented method,
- whether a manufacturer provides instructions or materials that induce the method steps.
The claim breadth includes multiple psychiatric indications; the more broadly the real-world practice adopts genotype-guided dose reduction, the higher the risk of method infringement exposure.
What Orange Book status is relevant to US 12,606,869, and what does method claiming do to exclusivity?
Method claims typically do not create Orange Book “exclusivity” in the same way as drug substance or formulation patents. The practical enforcement vehicle is patent litigation or licensing, not FDA exclusivity blocks.
Key business implication: even if a generic can file for approval, method patents can still be asserted to delay commercial launch via settlement or carve-outs, depending on litigation posture and risk tolerance.
Key Takeaways
- US 12,606,869 is a CYP2D641/41 genotype-guided iloperidone (or metabolite P88) dose reduction patent tied to lower QTc prolongation risk versus a 24 mg/day wild-type reference dose.
- The patent’s enforceability hinges on the combined presence of:
- CYP2D6 genotype definition (two *41 alleles),
- dose fraction definition (25/50/75% of 24 mg/day), and
- an explicit QTc-risk relationship limitation.
- Dependent claims narrow enforcement through:
- assay mechanistic requirements (DNA/mRNA extraction + amplification + probe hybridization sequencing),
- specific absolute doses (~6/12/18 mg/day),
- additional psychiatric indications,
- bid regimen,
- and metabolite P88 coverage.
- The dose fractions map cleanly to absolute targets:
- 25% = 6 mg/day, 50% = 12 mg/day, 75% = 18 mg/day, which improves infringement mapping for competitors and clinicians.
FAQs
1) Does US 12,606,869 require measuring actual QTc outcomes, or is the “lower QTc risk” limitation sufficient as claimed?
The claims require the method to be one where the QTc prolongation risk is lower following the first amount than if the compound were administered in the second amount; they do not state that a clinician must empirically measure QTc in a particular patient outcome during the method, as written in the provided claim text.
2) Can a different CYP2D6 genotype (non-*41) avoid infringement?
Yes, the claims as provided require a genotype that includes *two CYP2D641 alleles** for the core limitations in claims 1, 4, and 7.
3) If a clinician uses 80% of 24 mg/day for CYP2D641/41 patients, does the patent cover that?
Not based on the provided claims: claim 1 and claim 4/7 define the first amount as one of 25%, 50%, or 75% of 24 mg/day.
4) Is the metabolite P88 required for coverage, or does the patent cover iloperidone itself?
Iloperidone itself is covered as the compound is “iloperidone or a metabolite thereof.” P88 is specifically enumerated in dependent claims.
5) Does bid dosing (claims 19–20) have to match exactly to infringe?
Bid dosing is an added limitation in dependent claims. A method practicing claim 19/20 steps must use the bid regimen as claimed; independent claim scope is not restricted to bid unless the dependent limitations are invoked.
References
No sources were cited because no external patent record, prosecution history, issuing date, assignee, related US family members, or Orange Book listings were provided in the prompt.
